Elvitegravir 相關新聞
Elvitegravir 目前有 2 則相關新聞報導,預測適應症 20 個。
本頁整合 Elvitegravir 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
- 原適應症:Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated...
- 證據等級:L5
- 預測適應症(20 個):
- HIV infectious disease(99.9%)
- feline acquired immunodeficiency syndrome(99.9%)
- simian immunodeficiency virus infection(99.9%)
- neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter(99.9%)
- AIDS(99.5%)
- congenital human immunodeficiency virus(99.0%)
- AIDS related complex(99.0%)
- chronic hepatitis C virus infection(98.7%)
- hepatitis C virus infection(96.8%)
- hepatitis E virus infection(95.8%)
- hepatitis A virus infection(95.6%)
- Omsk hemorrhagic fever(95.6%)
- obsolete familial combined hyperlipidemia(95.6%)
- Kyasanur forest disease(95.5%)
- hepatitis, viral, animal(95.5%)
- hepatitis B virus infection(95.4%)
- fibroma of prostate(94.4%)
- Brenner tumor(94.3%)
- benign reproductive system neoplasm(94.2%)
- benign prostate phyllodes tumor(94.0%)
相關新聞(2 則)
Wirkstoff: Apilimod blockiert Viruseintritt in Leberzellen bei Hepatitis E
2026-04-27 hepatitis
來源:mt-portal.de
“Queremos aprovechar la experiencia de la estrategia frente a la hepatitis C para mejorar el abordaje global de la enfermedad hepática”
2026-04-26 hepatitis
來源:iSanidad
免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。